Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aetna: Entresto’s Label Enabled Outcome-Based Risk Share

Executive Summary

Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.

You may also be interested in...



Novartis Woos Payers With Data Showing Entresto Earns Its Keep

With Entresto sales slowly climbing to $53m in third quarter, Novartis releases data supporting value of heart failure drug in preventing costly hospitalizations at the annual American Heart Association meeting.

Smart Segmentation: Success In The Payer-Dominated Pharma Marketplace

As physicians lose decision-making authority to payers, argues Roger Longman of Real Endpoints, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs' use.

Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel